Lars Kliesch Pedersen

Lars Kliesch Pedersen serves as a Clinical Associate Professor in the Department of Clinical Medicine at the University of Copenhagen, specializing in Respiratory Medicine within Internal Medicine. His clinical work is based at Blegdamsvej 3 in Copenhagen and he maintains a professional connection with the Capital Region of Denmark (Region H), as indicated by his institutional email address.

Dr. Pedersen's research interests span multiple interconnected domains including respiratory conditions in athletes, cardiac-respiratory interactions, and post-infectious respiratory complications. His work demonstrates particular expertise in exercise-induced respiratory conditions, respiratory infections in athletic populations, and the cardiovascular implications of respiratory diseases. He has made significant contributions to understanding long-term respiratory complications following viral infections, including COVID-19.

Analysis of his recent publication record reveals a strong focus on practical clinical applications with international relevance. His work frequently appears in high-impact sports medicine and respiratory journals, with notable contributions to International Olympic Committee consensus statements. His research demonstrates consistent collaboration across multiple institutions and countries, reflecting the international nature of sports medicine research.

While specific grant information isn't detailed in the available text, Dr. Pedersen's participation in multicenter trials like the TARGET ABC study and the ACOVID study suggests involvement in significant research funding initiatives. His work on IOC consensus statements indicates recognition as an expert in respiratory conditions affecting athletes.

Dr. Pedersen's research appears to be conducted within multidisciplinary teams that bridge respiratory medicine, cardiology, and sports medicine. His involvement in studies examining long COVID in both hospitalized and non-hospitalized patients suggests participation in comprehensive clinical assessment teams that address the complex, multisystem nature of post-viral conditions.